JAMES FONTENOT: Open Payments
NPI 1770524332 · VILLE PLATTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$822 in 49 payments from 14 companies in 2025. Trend: 2023 $766 · 2024 $616 · 2025 $822
Food & beverage: $822
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 14 | $149 |
| AstraZeneca Pharmaceuticals LP | 7 | $145 |
| Axsome Therapeutics, Inc. | 4 | $100 |
| Lilly USA, LLC | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| PFIZER INC. | 3 | $52 |
| Ardelyx, Inc. | 3 | $48 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| Novo Nordisk Inc | 2 | $30 |
Products named: GEMTESA, Auvelity, MOUNJARO, FARXIGA, BREZTRI, CAPLYTA, TRELEGY ELLIPTA, ELIQUIS.
Industry payments across LA — which companies pay providers there.
